logo

For the Inventor, By the Inventor

Pasadena, CA, United States of America

Xencor, Inc.


USPTO Granted Patents = 227

% Expired Patents = 7.0



Trademarks = 5

Forward Citations = 3,848

Loading Chart...
Loading Chart...

110 inventors (with patents filed for the assignee):

goldMedal John R Desjarlais (177 out of 178 patents)

silverMedal Matthew J Bernett (103 out of 105 patents)

bronzeMedal Gregory Alan Lazar (89 out of 99 patents)

4.  Gregory L Moore (83 out of 84 patents)

5.  Sher Bahadur Karki (70 out of 70 patents)

6.  Rumana Rashid (55 out of 55 patents)

7.  Seung Yup Chu (53 out of 53 patents)

8.  Omid Vafa (33 out of 37 patents)

9.  Wei Dang (32 out of 32 patents)

10.  Robert J Hayes (32 out of 33 patents)

11.  Bassil I Dahiyat (31 out of 38 patents)

12.  Umesh Muchhal (25 out of 26 patents)

13.  Rajat Varma (23 out of 23 patents)

14.  Arthur J Chirino (20 out of 20 patents)

15.  Michael Hedvat (19 out of 19 patents)


Core Competencies:
Heterodimeric Antibodies
Fc Fusion Proteins
CD3 Targeting
PSMA Binding
IL-15
Bispecific Antibodies
CTLA4-IG
Immunotherapy
Checkpoint Inhibitors
IgE-Mediated Disorders
Neurological Diseases
Optimized Fc Variants

227 patents:

1. 12703748 - Anti-CD28 compositions (2026-08-11),
2. 12698341 - ANTIGEN BINDING DOMAINS THAT BIND TO MESOTHELIN (MSLN) (2026-08-04),
3. 12655230 - HETERODIMERIC ANTIBODIES THAT BIND CD3 AND GPC3 (2026-06-16),
4. 12617872 - HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS (2026-05-05),
5. 12559572 - NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS (2026-02-24),
6. 12509518 - METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES (2025-12-30),
7. 12509495 - LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS (2025-12-30),
8. 12497457 - METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES (2025-12-16),
9. 12492253 - ANTI-HUMAN C5 ANTIBODIES (2025-12-09),
10. 12486311 - NOVEL CTLA4-IG IMMUNOADHESINS (2025-12-02),
11. 12466897 - HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS (2025-11-11),
12. 12448423 - Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains (2025-10-21),
13. 12415849 - Heterodimeric proteins (2025-09-16),
14. 12404329 - Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 (2025-09-02),
15. 12398207 - Heterodimeric antibodies that bind CD3 and CLDN6 (2025-08-26),
Xencor, Inc. is a biopharmaceutical company specializing in the development of engineered monoclonal antibodies for the treatment of severe diseases. Their unique technology platform enables the creation of antibody drugs with enhanced therapeutic properties, improving patient outcomes. Xencor's focus areas include oncology, autoimmune disorders, and allergic diseases. Through their innovative approach, Xencor aims to transform the lives of patients by advancing the understanding and application of monoclonal antibody therapeutics.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Xencor, Inc.
227 Patents

#2 in Pasadena, CA

#399 in California

#1,843 in US

#3,768 in the World

Pasadena, CA (US)
Pasadena, CA, United States of America

Xencor, Inc.

Forward Citations = 3,848

110 inventors:

goldMedal John R Desjarlais (177 out of 178 patents)

silverMedal Matthew J Bernett (103 out of 105 patents)

bronzeMedal Gregory Alan Lazar (89 out of 99 patents)

4.  Gregory L Moore (83 out of 84 patents)

5.  Sher Bahadur Karki (70 out of 70 patents)

Please report any incorrect information to [email protected]
Loading…